Previous 10 | Next 10 |
Summary Harris Associates’ 13F portfolio value decreased from $62.85B to $59.68B this quarter. They added Warner Bros. Discovery and increased Salesforce, KKR, and Oracle while decreasing Keurig Dr Pepper and Humana. The top three positions are Alphabet, Fiserv, and Amazon.co...
Japanese regulators have granted marketing authorization to Regeneron's ( NASDAQ: REGN ) Libtayo (cemiplimab) for advanced or recurrent cervical cancer. Approval was based on the results of the phase 3 EMPOWER-Cervical 1 trial which enrolled participants regardless of PD-...
Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer PR Newswire TARRYTOWN, N.Y. , Dec. 23, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in ...
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine PR Newswire Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the ...
Summary The top net payout yield stock failed to match the total return of the S&P 500 during 2H '22 as tech stocks soared. The top net payout yield stocks averaged massive 19.6% yields to start December, as normal capital return plans returned during 2022. eBay claimed the top ...
Summary In-vivo CRISPR/Cas9 knock out gene editing treatments NTLA-2002 and NTLA-2001 have established proof of concept in treating patients with HAE and ATTR, respectively. Company has already gained the interest from big pharma for its CRISPR/Cas9 knock out gene editing technology pla...
Summary Intellia is the first to show data in a tough field of medicine. The one-off offering has a sound attractiveness to it. The key question is: will it succeed? I am surprised to see that I have never covered Intellia ( NTLA ), among the three pioneers in the gene...
Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire TARRYTOWN, N.Y. , Dec. 19, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41 st Annual J.P. Morgan Heal...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis PR Newswire If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic esophagi...
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis PR Newswire Approval based on direct-to-Phase 3 program showing more than three times as many Dupixent patients (60% and 58%) experienced clinical...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...